Candida auris is considered a serious fungal pathogen frequently exhibiting a high resistance to a wide range of antifungals. In this study, a combination of the quorum-sensing molecule farnesol (FAR) and fluconazole (FLU) was tested on FLU-resistant C. auris isolates (C. auris S and C. auris R) compared to the susceptible C. auris H261. The aim was to assess the possible synergy between FAR and FLU, by reducing the FLU minimal inhibitory concentration, and to determine the mechanism underlying the conjunct effect. The results confirmed a synergic effect between FAR and FLU with a calculated FIC index of 0.75 and 0.4 for C. auris S and C. auris R, respectively. FAR modulates genes involved in azole resistance. When FAR was added to the cells in combination with FLU, a significant decrease in the expression of the CDR1 gene was observed in the resistant C. auris isolates. FAR seems to block the Cdr1 efflux pump triggering a restoration of the intracellular content of FLU. These results were supported by observed increasing accumulation of rhodamine 6G by C. auris cells. Moreover, C. auris treated with FAR showed an ERG11 gene down-regulation. Overall, these results suggest that FAR is an effective modulator of the Cdr1 efflux pump in C. auris and, in combination with FLU, enhances the activity of this azole, which might be a promising strategy to control infections caused by azole-resistant C. auris.
Candida auris, in recent years, has emerged as a dangerous nosocomial pathogen. It represents a challenge for effective treatment because of its multiresistance. Photodynamic inactivation (PDI) is a promising way to solve problems with a wide range of resistant microorganisms. This study aimed to use PDI for the eradication of C. auris biofilms. Moreover, the regulation of the CDR1, CDR2, and MDR1 resistance genes was studied. Experiments were performed on 24 h biofilms formed by three clinical isolates of C. auris in vitro. PDI was performed in the presence of the photosensitizer methylene blue (0.25 mM) and samples were irradiated with a red laser (λ = 660 nm, 190 mW/cm2) for 79, 120, and 300 s. To confirm the PDI effect, confocal laser scanning microscopy was performed after treatment. Effective PDI was achieved in all strains. The highest inhibition was observed after 300 s irradiation, with over 90% inhibition compared with the non-irradiated control sample. PDI was observed to upregulate the expression of the CDR1 gene, but mainly the MDR1 gene. Despite this observation, PDI significantly decreased the survival of C. auris biofilm cells and proved to have great potential for the eradication of problematic resistant yeasts.
Verapamil (VER) is a calcium channel blocker used to treat cardiovascular diseases. However, some studies also suggest its antimicrobial potential. Changes in calcium abundance in yeasts can lead to decreased expression of transcription factors for genes related to morphology, resistance, and biofilm. Hyphal growth in Candida albicans is necessary for biofilm formation, especially in mixed biofilms with Staphylococcus aureus. This research studied the antibiofilm activity of VER in mixed biofilms of C. albicans SC5314 and S. aureus CCM3953. First, the minimal inhibitory concentration of VER was determined for single-species biofilms. Subsequently, a subinhibitory concentration of VER (1 mM) was tested on mixed biofilms. Biomass was reduced by 20% for C. albicans and 30% for S. aureus. The morphology of C. albicans was altered, and a decrease in S. aureus cells was also observed. qPCR was used to determine changes in HWP1 and ALS3 gene expression in biofilms formed w/wo VER. A decrease in the expression of both genes was observed. In vivo experiments with Galleria mellonella confirmed the antibiofilm activity of VER against mixed infections of C. albicans and S. aureus. These results suggest that VER regulates the morphology of C. albicans, resulting in changes in biofilm composition and the adhesion of S. aureus.
The prevalence of carbapenemase (CPE)-producing K. pneumoniae isolates has increased in hospitals worldwide over the past decade. Resistance is often associated with the ability of clinical isolates to form biofilm. The main objective was to investigate biofilm development in 30 hospital isolates of K. pneumoniae with confirmed CPE production as well as to analyze the distribution of resistance genes, the frequency of virulence genes, and their role in the regulation of biofilm. Selected isolates of K. pneumoniae with CPE production were examined for their ability to form biofilms using crystal violet staining. The presence of resistance genes (blaSHV1, blaTEM1, blaCTXM1) and genes (fimH, mrkD, entB) associated with biofilm formation was confirmed by PCR. Quantitative real-time PCR was then performed to compare the expression of biofilm-associated genes in weak, moderate and strong biofilm formers among K. pneumoniae. More than 50% of all K. pneumoniae isolates were confirmed to be strong biofilm producers. PCR confirmed the presence of resistance-associated genes and genes important for biofilm development in all clinical isolates tested. Additionally, qPCR showed increased regulation of the adhesion-related genes fimH and mrkD in moderate or strong biofilm formers of K. pneumoniae compared to weak biofilm formers. The present results provide valuable information on the relationship between increased CPE resistance, biofilm production, and its genetic regulation in K. pneumoniae hospital isolates.